XmAb968

P1, N=22, Active, not recruiting, Ehab L Atallah | Recruiting --> Active, not recruiting | N=60 --> 22 | Trial completion date: Oct 2026 --> Apr 2025 | Trial primary completion date: Oct 2025 --> Apr 2024

Major exclusion criteria are hematopoietic cell transplantation within 6 months of enrollment, prior therapy with daratumumab in the last 6 months and active acute graft-versus-host disease. XmAb18968, a novel CD-38 bispecific antibody appears safe and is showing response at the starting dose level in T-ALL. The study is currently enrolling additional patients with T-ALL. Updated analysis with additional patients and details on correlative studies examining mechanisms of therapeutic efficacy will be reported at the main meeting.

Twelve of 13 patients (92%) were previously treated with venetoclax based regimen and 31% had prior allogeneic HCT. XmAb18968 is safe and well tolerated in patients with RR-AML. Dose escalation yielded MRD negative CR in RR-AML patients who were MRD positive at study entry. Details on correlative studies examining mechanisms of therapeutic efficacy and resistance will be reported in the main meeting.

P1, N=60, Recruiting, Ehab L Atallah | Not yet recruiting --> Recruiting

P1, N=60, Not yet recruiting, Ehab L Atallah | Initiation date: Oct 2021 --> Jan 2022

P1, N=60, Not yet recruiting, Ehab L Atallah

These findings support the clinical development of AMG 424, an affinity-optimized T cell-recruiting antibody with the potential to elicit significant clinical activity in MM patients.